Passage Bio IncPASG
Price$4.20

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$36.1MTTM through 30 Jun 2026
Free Cash Flow -$33.5MTTM through 30 Jun 2026

Margins

Current

Returns

-321.0%ROE
-103.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio1.73x
Net Debt-$33.3Mnet cash position
Cash & Equivalents$24.2M

Quality Metrics

Altman Z-Score-44.49
Piotroski F-Score2 / 9
Earnings-Beat Rate66.7%

Multi-Year Trend

Diluted EPS-$11.32TTM
'20'21'22'23'24'25
FY2025: $-14.35

Dividend

No dividend

Capital Allocation

R&D Spend$17.2M

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.